PHAR News and Press, Pharming Group N.V. From 03/27/23

2023-03-27 13:06:40 ET Gainers: WiSA Technologies ( WISA ) +93% . First Citizens BancShares ( FCNCA ) +50% . Alimera Sciences ( ALIM ) +38% . Cimpress ( CMPR ) +30% . Gorilla Technology Group ( GRRR ) +25% . CBL International...

2023-03-27 08:52:49 ET Unity Biotechnology UBX -47% after mid-stage setback for wet AMD candidate . NuCana ( NCNA ) -28% after the European Patent Office issues oral ruling that NuCana's '190 patent is not valid . Pharming Group PHAR -13% erasing today'...

2023-03-27 05:45:26 ET The shares of Dutch biotech Pharming Group N.V. ( NASDAQ: PHAR ) added ~24% on Monday in the Amsterdam stock exchange on the announcement of U.S. approval for the rare immune disorder therapy Joenja co-developed with Novartis ( NVS ). The FDA...

2023-03-24 15:00:32 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...

Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS Canada NewsWire APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary immunodeficiency Joenja® is a ta...

2023-03-16 10:04:06 ET Pharming Group N.V. (PHGUF) Q4 2022 Earnings Call Transcript March 16, 2023 08:30 AM ET Company Participants Sijmen de Vries - Executive Director & Chief Executive Officer Anurag Relan - Chief Medical Officer Jeroen Wakkerman - Chief Fi...

2023-03-16 08:53:37 ET The following slide deck was published by Pharming Group N.V. in conjunction with their 2022 Q4 earnings call. For further details see: Pharming Group N.V. 2022 Q4 - Results - Earnings Call Presentation

Pharming announces first patient enrolled in pediatric clinical trial of leniolisib Canada NewsWire The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency LEIDEN, Netherlands ...

A panel of the European Medicines Agency (EMA) converted the review of Pharming's ( NASDAQ: PHAR ) drug leniolisib to standard review from accelerated assessment as the committee sent questions to the company, including requesting more data. The company's marketing authoriza...

Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe Canada NewsWire EMA Marketing Authorisation Application for leniolisib changed to standard review timetable LEIDEN, Netherlands , Feb. 16, 2023 /CNW/ -- Pharming Group N.V. ("P...